Skip to main content
    C

    Compass Pathways Plc (CMPS)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $8.27
    -0.74 (-8.21%)

    Market Cap: $1.28B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Compass Pathways Plc (CMPS) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Compass Pathways Plc (CMPS) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Compass Pathways Plc reported EPS of -$0.31, above the -$0.39 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    62%(16/26)
    Avg Surprise
    +3.70%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.47
    Range-$0.59 - -$0.34
    17 analysts
    Revenue Consensus
    N/A
    RangeN/A
    15 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.38
    Range-$0.38 - -$0.38
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.47+19.1%
    60d ago-$0.39+2.6%
    30d ago-$0.39+2.6%
    7d ago-$0.39+2.6%
    Current-$0.38
    Revenue Consensus
    $71.43K
    RangeN/A
    7 analysts

    Next Report

    CMPS has an expected report date of Mar 22, 2027.

    CMPS Earnings Call

    The latest CMPS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 26 quarters below that had an estimate, CMPS beat 16, missed 9 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 62.59% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.31-$0.39-$0.41 - -$0.25+20.51%BeatN/A40 up, 1 downNov 3, 2026
    Jun 30, 2026-$0.36-$0.46N/A+21.74%BeatN/A40 up, 0 downAug 5, 2026
    Mar 31, 2026-$0.30-$0.31-$0.35 - -$0.28+3.23%BeatN/A21 up, 1 downMay 13, 2026
    Dec 31, 2025-$0.61-$0.40-$0.42 - -$0.36-52.66%MissN/A22 up, 0 downMar 24, 2026
    Sep 30, 2025-$0.38-$0.40-$0.41 - -$0.40+5.00%BeatN/A22 up, 0 downNov 4, 2025
    Jun 30, 2025-$0.41-$0.37-$0.37 - -$0.37-10.81%MissN/A22 up, 0 downJul 31, 2025
    Mar 31, 2025-$0.42-$0.49-$0.67 - -$0.41+14.29%BeatN/A51 up, 0 downMay 8, 2025
    Dec 31, 2024-$0.63-$0.63-$0.75 - -$0.560.00%In lineN/A71 up, 3 downFeb 27, 2025
    Sep 30, 2024-$0.56-$0.59-$0.68 - -$0.48+5.08%BeatN/A90 up, 0 downOct 31, 2024
    Jun 30, 2024-$0.56-$0.55-$0.65 - -$0.44-1.82%MissN/A70 up, 0 downAug 1, 2024
    Mar 31, 2024-$0.55-$0.49-$0.68 - -$0.28-12.24%MissN/A50 up, 0 downMay 8, 2024
    Dec 31, 2023-$0.53-$0.34-$0.62 - -$0.24-55.88%MissN/A50 up, 0 downFeb 29, 2024
    Sep 30, 2023-$0.67-$0.42-$0.63 - -$0.19-59.52%MissN/A71 up, 0 downNov 2, 2023
    Jun 30, 2023-$0.62-$0.70-$0.81 - -$0.62+11.43%BeatN/A80 up, 0 downAug 3, 2023
    Mar 31, 2023-$0.57-$0.65-$0.81 - -$0.50+12.31%BeatN/A80 up, 0 downMay 11, 2023
    Dec 31, 2022-$0.73-$0.59-$0.69 - -$0.46-23.73%MissN/A80 up, 0 downFeb 28, 2023
    Sep 30, 2022-$0.43-$0.64-$0.73 - -$0.55+32.81%BeatN/A91 up, 0 downNov 3, 2022
    Jun 30, 2022-$0.50-$0.60-$0.66 - -$0.49+16.67%BeatN/A80 up, 0 downAug 4, 2022
    Mar 31, 2022-$0.50-$0.67-$0.73 - -$0.61+25.37%BeatN/A70 up, 0 downMay 10, 2022
    Dec 31, 2021-$0.61-$0.50-$0.60 - -$0.41-22.00%MissN/A90 up, 0 downFeb 24, 2022
    Sep 30, 2021-$0.38-$0.47-$0.57 - -$0.42+19.15%BeatN/A9N/ANov 9, 2021
    Jun 30, 2021-$0.44-$0.37-$0.45 - -$0.30-18.92%MissN/A8N/AAug 11, 2021
    Mar 31, 2021-$0.35-$0.47-$0.72 - -$0.33+25.53%BeatN/A4N/AMay 13, 2021
    Dec 31, 2020-$0.52-$1.39-$2.42 - -$0.36+62.59%BeatN/A3N/AMar 9, 2021
    Sep 30, 2020-$0.46-$0.68-$0.77 - -$0.33+32.35%BeatN/A3N/ANov 12, 2020
    Jun 30, 2020-$0.19-$0.35N/A+45.71%BeatN/AN/AN/ASep 21, 2020
    Dec 31, 2019-$0.35N/AN/AN/AN/AN/AN/AN/ADec 31, 2019
    Sep 30, 2019-$0.26N/AN/AN/AN/AN/AN/AN/ASep 30, 2019
    Jun 30, 2019-$0.45N/AN/AN/AN/AN/AN/AN/AJun 30, 2019
    Mar 31, 2019-$0.48N/AN/AN/AN/AN/AN/AN/AMar 31, 2019
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.82, after -$2.30 the year before. It was -$2.35 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.82N/A
    Dec 31, 2024-$2.30N/A
    Dec 31, 2023-$2.39N/A
    Dec 31, 2022-$2.16N/A
    Dec 31, 2021-$1.78N/A
    Dec 31, 2020-$1.17N/A
    Dec 31, 2019-$0.90N/A
    Dec 31, 2018-$2.35N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 19 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,21019
    2026Q2Jun 30, 20265,87517
    2026Q1Mar 31, 20267,91117
    2025Q3Sep 30, 20254,39213
    2025Q2Jun 30, 20254,09414
    2025Q1Mar 31, 20252,4879
    2024Q4Dec 31, 20245,80517
    2024Q3Sep 30, 20246,20017

    2026Q3 Earnings Call

    Opening remarks

    Stephen Schultz Senior Vice President of Investor Relations Welcome, all of you, and thank you for joining us today for this conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. Today, I am joined by Kabir Nath, our Chief Executive Officer, and Lori Englebert, our Chief Commercial Officer. Dr. Steve Levine, our Chief Patient Officer, and Teri Loxam, our Chief Financial Officer, will also be available for the Q&A. The call is being recorded and will be available on the Compass Pathways Investor Relations website shortly after the conclusion of the call, and will be available for a period of 30 days. Before we begin, let me remind everyone that during the call today, we will be making statements about our future plans and prospects that constitute forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement, including those risks and uncertainties described under the heading "Risk Factors" in our most recent filings with the U.S. Securities and Exchange Commission. These forward-looking statements represent our views only as of today, and we specifically disclaim any obligation to update or revise any forward-looking statement, even if our estimates or assumptions change. I will now hand the call to Kabir Nath.

    Kabir Nath CEO Thank you, Steve, and thank you all for joining us today. Compass continues to make excellent progress toward the potential FDA approval of our psychedelic treatment, which will fundamentally change how mental health is managed. Today, for the estimated 4 million individuals in the U.S. who are impacted by treatment-resistant depression, there is only one approved and marketed drug with that indication, and fewer than 3% of those patients are actually being treated with it. COMP360's profile is unique and compellingly differentiated in delivering both a rapid onset, with effects seen within 24 hours, and durability potentially out to 12 months with just a few treatments. The data also show a safety profile that is generally well tolerated. We're confident that COMP360's efficacy in this difficult-to-treat patient population, along with a much less frequent administration schedule, will be highly attractive to patients and prescribers, a confidence that's been well supported by the recent market research that we've been conducting. We will complete our rolling NDA submission in the next two weeks. We have ensured that the filing is the highest quality, with two highly statistically significant phase III studies, together with a positive phase II-B study that together enrolled over 1,000 patients. This will enable the agency to review it with its usual scientific rigor.

    Frequently Asked Questions About CMPS

    When is Compass Pathways Plc's next earnings date?

    Compass Pathways Plc's next earnings report is expected for Mar 22, 2027.

    Did CMPS beat earnings estimates last quarter?

    Yes. Compass Pathways Plc reported EPS of -$0.31 for the quarter ended Sep 30, 2026, above the -$0.39 estimate, a 20.51% surprise.

    What EPS do analysts expect from CMPS next quarter?

    The consensus EPS estimate for Compass Pathways Plc for the quarter ending Dec 31, 2026 is -$0.47 from 17 analysts, with estimates from -$0.59 to -$0.34.

    How often does CMPS beat earnings estimates?

    Compass Pathways Plc beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.16%.